Ok, go ahead and invest the farm on OPTR if this is such a slam dunk.....or you can open your eyes.....I have outline my short thesis in prior posts and is not worth rehashing since every one on this board is so delusional and don't care to see or consider. This will be my last post for a while, but trust I'll be back to either be congratulated or be proven wrong (although based on my research I expect to be proven right).....time will indeed tell.
proinvestor, I have always thought that you are knowledgeable.It is important to see both sides of the story as I am just a retail investor sold on a drug that I really believe can extend life and minimize suffering.I have had a bout of c diff and maybe that is why I am very passionate about this antibiotic.
You aren't going to find anyone to do that based on these results. Fidaxomicin has been shown to treat C. Difficile as well as Vancomycin except in one area. Fidaxomicin has demonstrated statistically significant superiority to Vancomycin in reducing reoccurring incidences of C. Difficile. Keep in mind that in 2007 Vancomycin had an estimated $380 mil in US sales alone. Not even that hack probasher2010 can trump up anything against these results. OPTR will be approved.